Results 91 to 100 of about 17,802 (177)

Disseminated Cryptococcosis under Fingolimod Therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler, Morna F. Schmidt, Ana Ortins‐Pina, David Kluwig, Amir S. Yazdi   +4 more
wiley   +1 more source

Panzytopenie durch Fingolimod: Hypothese eines neuen Mechanismus

, 2019
Der Wirkstoff Fingolimod ist in Deutschland als krankheitsmodifizierende Monotherapie von hochaktiver schubförmig-remittierend verlaufender Multipler Sklerose bei bestimmten Patienten zugelassen.
Held, T., Hichert, V.
core   +1 more source

Fingolimod Suppresses NLRP3 Inflammasome Activation and Alleviates Oxidative Stress in Traumatic Brain Injury-Induced Acute Lung Injury [PDF]

Qi Shi,1,* Tingting Hu,2,* Lixia Xu,2,* Jiayuanyuan Fu,1 Yehong Fang,1 Yu Lan,1 Weijia Fan,2 Qiaoli Wu,2 Xiaoguang Tong,1– 3 Hua Yan1– 3 1Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Medical University, Tianjin,
Xu L, Fang Y, Fan W, Hu T, Wu Q, Shi Q, Fu J, Tong X, Yan H, Lan Y   +9 more
core  

Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis

Neurology and Therapy
Introduction Fingolimod (Gilenya®), commonly used for relapsing-remitting multiple sclerosis (RRMS), is the first approved oral immunomodulatory agent.
Feliciana Menna, Lucilla Barbano, Carmen Dell’Aquila, Mattia D’Andrea, Vincenzo Parisi, Lucia Ziccardi   +5 more
doaj   +1 more source

Investigation of the Effects of Fingolimod on the LPS-Induced Inflammatory Response in the HUVEC Cell Line

Pharmata
Aim: The objective of this study was to examine the impact of fingolimod on tumour necrosis factor-alpha (TNF-α) production in the context of a lipopolysaccharide (LPS)-induced inflammatory response in a human umbilical vein endothelial cells (HUVEC ...
Hamza Halıcı, Eda Yilmaz
doaj   +1 more source

Acute onset of fingolimod-associated macular edema [PDF]

, 2016
PurposeFingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs ...
Quan Dong Nguyen, Mohamed Kamel Soliman, Zabad, Rana K., Nguyen, Quan Dong, Jack, Loren, Neil Jouvenat, Sadiq, Mohammad A., Soliman, Mohamed Kamel, Mohammad A. Sadiq, Loren Jack, Sarwar, Salman, Kedar, Sachin, Salman Sarwar, Jouvenat, Neil, Sachin Kedar, Rana K. Zabad   +15 more
core   +1 more source

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

, 2006
BACKGROUND Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis. METHODS We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo ...
Antel J, Korn AA, Kappos L, O'Connor P, Polman CH, Montalban X, Karlsson G, Comi G, Radue EW, Haas T   +9 more
core   +1 more source

Population Pharmacokinetics of Fingolimod Phosphate in Healthy Participants.

, 2011
Fingolimod (FTY720) is a sphingosine 1-phosphate receptor (S1PR) modulator currently being evaluated for the treatment of multiple sclerosis. Fingolimod undergoes phosphorylation in vivo to yield fingolimod phosphate (fingolimod-P), which modulates S1PRs
Wu, Kai, Mercier, Francois, David, Olivier J, Robert L. Schmouder, Francois Mercier, Kai Wu, Looby, Michael, Michael Looby, Schmouder, Robert L, Olivier J. David   +9 more
core   +1 more source

Life-threatening asthma attack during prolonged fingolimod treatment: case report

, 2014
Chiara Zecca,1,* Matteo Caporro,1,* Sandor Györik,2 Claudio Gobbi11Neurocenter of Southern Switzerland, Department of Neurology, Ospedale Regionale di Lugano, Lugano, Switzerland; 2Department of Internal Medicine, Ospedale Regionale di Bellinzona ...
Zecca C, Györik S, Gobbi C, Caporro M   +3 more
core  

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis

, 2011
Clemens Warnke1,2, Olaf Stüve3,4, Hans-Peter Hartung1, Anna Fogdell-Hahn2, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany; 2Department of Clinical Neuroscience, Karolinska Institute, Stockholm,
Hartung HP, Fogdell-Hahn A, Kieseier B, Warnke C, Stüve O   +4 more
core